Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Authors:
Top Cited Papers
- 29 October 2021
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 9 (12) , 1427-1438
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- VIB
- Bijzonder Onderzoeksfonds UGent
- Belgian Health Care Knowledge Centre
This publication has 38 references indexed in Scilit:
- Characterization of the Inflammatory Response to Severe COVID-19 IllnessAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19Journal of Allergy and Clinical Immunology, 2020
- Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trialTrials, 2020
- Elevated interleukin‐6 and severe COVID‐19: A meta‐analysisJournal of Medical Virology, 2020
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- ARDS Subphenotypes: Understanding a Heterogeneous SyndromeCritical Care, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- A global clinical measure of fitness and frailty in elderly peopleCanadian Medical Association Journal, 2005